Home
Resources
Publications
Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

Jennifer L Babin, Katie L Traylor, Daniel M Witt

Semin Thromb Hemost. 2017 Apr;43(3):261-269.

PMID: 27281281

Abstract:

Compared with older agents, low-molecular-weight heparins (LMWH) and fondaparinux offer improved bioavailability and more predictable, dose-independent clearance. While routine monitoring of coagulation parameters is not usually necessary with these agents, certain populations (including pregnant patients, children, obese patients, and patients with renal impairment) may benefit from the monitoring of anti-factor Xa activity, thromboelastography, or other coagulation assays to help guide therapy. The chromogenic anti-factor Xa assay is currently the gold standard for monitoring LMWH and fondaparinux therapy. Thromboelastography has been used to monitor LMWH therapy in special situations but is not needed for routine use.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP114870030-A	Fondaparinux sodium for Assay		114870-03-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: